Clinical trial NCT06628037: SN514-066b Enzyme in Deep Partial Thickness Burns
Official title: A Phase 1 Maximum Tolerated Dose Study of SN514-066b in Adult Patients With Deep Partial Thickness Dermal Burns
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE1
PHASE2
Conditions: Burn Injury
Keywords: Maximum tolerated dose
Debridement
Lead sponsor: SERDA bv
Sponsor class: INDUSTRY
Collaborators: name: The Metis Foundation
First posted: 2024-10-04
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study will examine the tolerability of a gel formulation of the enzyme SN514 in patients with burns suitable for enzymatic debridement. In a rising dose fashion by sequential cohort, concentrations of 0.1%, 0.2%, 0.4% and 0.8% will be tested. Groups of 3 will undergo daily debridement for up to 7 days. Extent of debridement and adverse signs and symptoms will be recorded daily. Dose escalation will stop if a dose level is found to be intolerable. Dose escalation may accelerate if a tested dose is entirely ineffective. There is no placebo control as all burn wounds require debridement.

Detailed description: The design of the study is a sequential rising dose to the maximum tolerated dose, in which each subject will be exposed to only one concentration of the test article. Dose limiting toxicities are defined as "Severe" or CTCAE v5 Grade 3 or higher adverse events. This study in burn patients is designed to apply SN514-066b over 25 cm2 (0.14% TBSA for a 1.73 m2 adult) up to 500 cm2 (2.9%), at sequentially rising concentrations of 0.1%, 0.2%, 0.4% and 0.8% (\&lt; 1.0 mg/cm2). The highest exposure would be 0.8% (8 g per 100 cc of gel) over 2.9% of 1.73 m2 = 800 mg or 11.4 mg/kg applied topically (70 kg patient).

Eligibility criteria: Main Inclusion Criteria:

1. Thermal burns caused by fire/flame, scalds or contact
2. Total burns area available for treatment is 25 to 500 cm2 (a larger area may be burned, but the treatment area must be limited to the stated size, and the treatment area must be exclusive of face, hands, genitalia and sites deemed to be at high risk for developing compartment syndrome)
3. Target burns for treatment is deep partial thickness (DPT) in depth

Main Exclusion Criteria:

1. Subject has another life threatening traumatic injury
2. Patient's proposed study wound site has any of the following conditions:

   * Electrical or chemical etiology
   * Pre-enrollment escharotomy
   * Area is devoid of circulation
   * Located on the face, perineum or genitalia
   * Clinical evidence of wound infection
3. Poorly controlled diabetes mellitus (HbA1c \&gt;12%)
4. BMI greater than 40 kg/m2
5. Cardio-pulmonary disease (MI within 6 months prior to injury, severe or unstable ischemic heart disease, severe or unstable heart failure, severe pulmonary hypertension, severe COPD or pre-existing oxygen-dependent pulmonary diseases, severe broncho-pneumonia within 1 month prior to injury, steroid dependent asthma, or uncontrolled asthma)
6. Pre-existing diseases which interfere with circulation (severe peripheral vascular disease, severe circulatory edema and/or lymphedema, regional lymph nodes dissection, significant varicose veins)
7. Any conditions that would preclude safe treatment or adding further risk to the basic acute burn trauma (such as severe immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, severe cardiovascular disorder, significant pulmonary disorder, significant liver disorder including post alcoholic abuse impaired function or neoplastic disease, blast injury)

Primary outcomes:
measure: Determine the maximum tolerated concentration of SN514 gel when applied topically to deep partial thickness burn wounds
timeFrame: Daily x 7days
Secondary outcomes:
measure: Evaluate the time course and extent of debridement when applied daily for up to 7 days
timeFrame: Daily x 7days
measure: Evaluate effects of treatment on inflammation
timeFrame: Daily x 7days
measure: Observe the incidence of wound erythema
timeFrame: Daily x 7days
measure: Incidence of wound purulence
timeFrame: Daily for 7 days
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: USAISR Burn Center
state: Texas
Study officials:
References: